| This week's sponsor is Premier Research. | |  | iRECIST: The Future of Solid Tumor Evaluation?
The iRECIST guidance on solid tumor response focuses new attention on standardizing and validating immune response criteria. Will it be the new standard for clinical trials? See what our experts think. Premier Research. It's what we do. Best. |
Featured Story | | | Thursday, October 5, 2017 A report from CNBC says that PayPal founder Peter Thiel and Facebook investor Sean Parker are investing in a new, secretive oncology biotech company. |
|
|
| This week's sponsor is Deloitte. | |  | |
Top Stories Thursday, October 5, 2017 A single dose of Bluebird Bio’s gene therapy for cerebral adrenoleukodystrophy (cALD) stabilized the disease in 15 of 17 patients over more than two years of follow-up. Thursday, October 5, 2017 Visterra has extended its series C round to fund the advance of its lead candidate into phase 2b. The extension puts Visterra back on the multifront path through the clinic it plotted out before its aborted IPO attempt. Monday, October 2, 2017 Learn how one company sought support at multiple junctures—from manufacturing to biomarker evaluation to market access—to enable a faster and more effective launch of their new programmed death receptor-1 (PD-1)-blocking antibody. Thursday, October 5, 2017 AMR Centre has licensed a program from Medivir. The metallo-beta-lactamase inhibitors are designed to inactivate the NDM-1 mechanism, rendering drug-resistant bacteria vulnerable to beta-lactam antibiotics. Thursday, October 5, 2017 As part of our video series for this year’s DDF 2017 event, life science leaders spoke to us about CRO needs and new regulations. Thursday, October 5, 2017 CRISPR-Cas9 is a promising tool against genetic disease, but it comes with some safety concerns, namely, off-target gene editing that may bring about harmful side effects such as cancer. UC Berkeley scientists are using a new delivery system to more safely correct the mutated dystrophin gene in mouse models of Duchenne muscular dystrophy. Wednesday, October 4, 2017 A signaling pathway in the body called Hippo is well known in scientific circles for its potential role in cancer, but now scientists at Baylor believe they have found another place where manipulating this system could be beneficial—the heart. When they turned off the pathway in mouse models of heart failure, they were able to restore pumping ability to that of healthy hearts. Wednesday, October 4, 2017 Sixty-eight cancer drug indications won European approval between 2009 and 2013—but most of them did so without showing they could extend or improve life, a new study shows. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Sponsored by: Veeva Systems The 2017 Unified Clinical Operations Survey finds that 99% of respondents report the need to unify their clinical applications, including CTMS, EDC, eTMF, and study start-up. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. | 
